1. Home
  2. SHO vs AGIO Comparison

SHO vs AGIO Comparison

Compare SHO & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SHO

Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.

HOLD

Current Price

$10.80

Market Cap

1.8B

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$29.49

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHO
AGIO
Founded
1995
2007
Country
United States
United States
Employees
37
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SHO
AGIO
Price
$10.80
$29.49
Analyst Decision
Hold
Buy
Analyst Count
7
8
Target Price
$9.79
$38.88
AVG Volume (30 Days)
1.7M
750.9K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
3.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
$3.95
$76.75
Revenue Next Year
$2.30
$170.73
P/E Ratio
$966.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.43
$22.24
52 Week High
$11.05
$46.00

Technical Indicators

Market Signals
Indicator
SHO
AGIO
Relative Strength Index (RSI) 65.60 54.44
Support Level $8.81 $26.75
Resistance Level N/A $30.90
Average True Range (ATR) 0.23 1.09
MACD 0.03 0.28
Stochastic Oscillator 71.81 64.94

Price Performance

Historical Comparison
SHO
AGIO

About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.

Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in California which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its Hotel Ownership Segment.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: